Recording of Pharmacy First consultations in general practice records in England: an observational study of the service's first year using OpenSAFELY

Viveck J Kingsley[1*], Milan Wiedemann[1*], Christopher Wood[1], Amelia Green[1], Helen J Curtis[1], Louis Fisher[1], Colm D Andrews[1], Amelia C Taylor[4,5], Diane Ashiru-Oredope[3,6], Kimberley Sonnex[6], Thomas Allen[7], Hannah Higgins[3], Tracey Thornley[3,6], Nicholas Mays[2], Rebecca E Glover[2], Rachel A Elliott[5,7], Anthony J Avery[4,5], Brian MacKenna[1**]

[1] Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK

[2] London School of Hygiene and Tropical Medicine, Department of Health Services Research and Policy, 15-17 Tavistock Place, WC1H 9SH, London, UK

[3] UK Health Security Agency, London NW9 5EQ, UK

[4] Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, NG7 2RD

[5] NIHR Greater Manchester Patient Safety Research Collaboration, University of Manchester, Manchester, M13 9PL

[6] School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD

[7] Manchester Centre for Health Economics, University of Manchester, Manchester, M13 9PL

* These authors contributed equally to this work and share first authorship
** Corresponding author

Abstract

Background: Pharmacy First, a national community pharmacy service, launched in January 2024 to improve access to primary care for patients with minor conditions facing backlogs caused by the COVID-19 pandemic. Pharmacies are required to share details about their consultations with general practices. We aimed to describe how and what clinical activity was recorded in general practice during the first year of the service.

Methods: With the approval of NHS England, we conducted a retrospective cohort study using OpenSAFELY-TPP including Pharmacy First consultations between 31 January 2024 and 30 January 2025. We described patient demographics, consultation trends, and the clinical conditions and medications coded with Pharmacy First consultations.

Results: A total of 402,165 Pharmacy First consultations were recorded for 340,710 patients from a general population of 26,142,380 registered patients in OpenSAFELY-TPP. Acute pharyngitis (28.9%) and uncomplicated urinary tract infection (28%) were the most frequently recorded conditions. By January 2025, 36.3% of Pharmacy First consultations were recorded with a clinical condition, medication, or both. Females, younger adults and those living in more deprived areas were observed more often in Pharmacy First records compared to the general population.

Conclusion: Increasing recording of the Pharmacy First community pharmacy service was observed in general practice records during its first year, particularly among younger and more deprived populations. However, structured recording of consultation details remains incomplete, limiting evaluation and integration of the service into routine general practice workflows.

Keywords: Pharmacy First; general practice; community pharmacy

Background

The COVID-19 pandemic has had a significant impact on the access to and provision of health services in England. The English National Health Service (NHS) is a universal health care system which provides care that is typically free at the point of need. However waiting times for appointments with primary care doctors (general practitioners, GPs), have been increasing year-on-year (1,2). The main focus of community pharmacies in the UK has historically been the supply of medication but contract changes from NHS England have seen a move towards a more clinically focused service (3). In response to the delays and pressures on primary care doctors after COVID-19, NHS England, the national organisation responsible for the NHS in England, announced a recovery plan to "*make it easier and quicker for patients to get the help they need from primary care*" (4). A key element of the COVID-19 recovery plan is the Pharmacy First programme, which launched on 31st January 2024, and supports community pharmacists to follow specified clinical pathways to assess for and manage seven common conditions, and supply medications, including prescription-only medications, where appropriate (5,6).

Pharmacy First requires sharing of clinical record information between general practice (GP) and community pharmacy. NHS England mandated use of *GP Connect: Update Record* which enables registered pharmacies to send summaries of Pharmacy First consultations directly into the primary care records held by GPs (7). *GP Connect: Update Record* uses pre-specified Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) codes, a standardised set of clinical terms designed to support consistent recording and sharing of clinical information in electronic health records (8). This structured transfer aims to improve consistency and accuracy of recording Pharmacy First consultations and ensure information from the consultation is available in the GP record as quickly as possible to support clinical decision-making (9). However, the rollout of *GP Connect: Update Record* has been gradual, partly due to the involvement of four community pharmacy systems and two major GP system suppliers, each being ready at different timepoints (10).

To support the national implementation of Pharmacy First and to generate evidence of its impact, the National Institute for Health and Care Research commissioned an evaluation of the impact and implementation of Pharmacy First (11). This evaluation is a collaboration across five partner organisations, including using OpenSAFELY, a secure analytics platform for electronic health records developed by the Bennett Institute for Applied Data Science at the University of Oxford on behalf of NHS England. OpenSAFELY facilitates analyses on all patients' full raw pseudonymised primary care records, with patient-level linkage to various other data sources (12,13). This infrastructure enables near real-time insights into NHS service delivery, including how new services like Pharmacy First are adopted and recorded in general practice.

We aimed to describe how Pharmacy First Clinical Pathway activity was recorded in general practice records during the first year of the service, focusing on two main areas. The first aim was to examine and compare overall consultation activity in OpenSAFELY-TPP: (a) describe the patient population using the Pharmacy First service and compare it with the total

population registered with a GP; (b) identify monthly trends of Pharmacy First consultations in GP records and compare the activity with publicly available data from the NHS. The second aim was to assess the clinical information recorded in Pharmacy First consultations in OpenSAFELY-TPP: (c) describe the coding completeness of Pharmacy First consultations in GP records; (d) describe the clinical conditions and medications supplied under Pharmacy First in GP records.

Methods

Study Design and Population

This study employed a retrospective cohort design, using routinely collected electronic health record (EHR) data from the OpenSAFELY-TPP platform. The study period was 31st January 2024 to 30st January 2025 to capture the first year of the Pharmacy First service. The study population consisted of individuals recorded as male or female in the EHR, who were alive, aged between 0 and 120 years, had a Pharmacy First consultation, and were registered at a TPP general practice during the study period.

Data Sources

OpenSAFELY-TPP

Primary care records managed by the GP software provider TPP were accessed through OpenSAFELY (https://www.opensafely.org/), a secure analytics platform for EHRs built during the COVID-19 pandemic. OpenSAFELY operates within the data centres of EHR providers, allowing for analysis without transferring raw data outside the secure environment. Data were accessed from OpenSAFELY-TPP, which covers approximately 40% of the English population, and includes pseudonymised, structured data. Data from individuals who opted out of NHS data-sharing with their GP surgery (Type 1 Opt-out) were excluded and free-text data were also not included.

NHS BSA comparison data

To contextualise the Pharmacy First consultation data recorded in OpenSAFELY-TPP, we compared consultation counts with service activity data submitted for reimbursement by community pharmacies and published by NHS Business Services Authority (NHS BSA). NHS BSA provides publicly available records of monthly dispensing activity and service usage with a three-month delay. We used the *Pharmacy and appliance contractor dispensing dataset* which includes monthly counts of Pharmacy First Clinical Pathways covering all pharmacies in England that have submitted a claim (14).

Identification of clinical events and medications

We developed reusable Electronic Health Records Query Language (ehrQL) code that extracts Pharmacy First consultations together with associated clinical conditions and medications, see box 1.

Box 1. Identify clinical conditions and medications of Pharmacy First consultations through consultation identifiers in OpenSAFELY.

```python
# Identify all clinical events and medications coded during Pharmacy First
# consultations using consultation IDs. Using consultation IDs allows us to
# identify clinical information of the same event across different datasets.

# Define SNOMED CT codelist with Pharmacy First consultation codes
pharmacy_first_codelist = [
  "1577041000000109",
  "983341000000102",
  "2129921000000100",
]

# Get all Pharmacy First consultation IDs
pharmacy_first_ids = clinical_events.where(
  clinical_events.snomedct_code.is_in(pharmacy_first_codelist)
).consultation_id

# Select all other clinical events with the same consultation IDs
selected_pharmacy_first_events = clinical_events.where(
  clinical_events.consultation_id.is_in(pharmacy_first_ids)
)

# Select all medications issued with the same consultation IDs
selected_pharmacy_first_medications = medications.where(
  medications.consultation_id.is_in(pharmacy_first_ids)
)
```

Pharmacy First consultations

The *GP Connect: Update Record* technical documentation (8) specifies that pharmacies providing the service should use the *Community Pharmacist Consultation Service for minor illness* (1577041000000109) code. Using *OpenCodelists* (https://www.opencodelists.org/), we identified two further SNOMED CT codes that could be associated with Pharmacy First consultations: *Pharmacy First Service* (983341000000102) and *Community Pharmacy Pharmacy First Service* (2129921000000100).

Pharmacy First clinical conditions

As specified by NHS England, the Pharmacy First service includes the supply of medication for seven clinical conditions: acute otitis media, impetigo, infected insect bites, herpes zoster, acute sinusitis, acute pharyngitis, and uncomplicated urinary tract infection (5). To identify these clinical conditions within Pharmacy First consultations, we implemented the clinical conditions codelist issued by NHS England (15). This codelist included a single code for each condition as specified by NHS England. Each clinical condition has NHS England-defined inclusion and exclusion criteria, applied at the time of consultation to determine treatment eligibility (16). Our analysis included all consultations recorded with a Pharmacy First consultation code, regardless of eligibility.

Pharmacy First medications

We developed medication codelists, using the NHS standard dictionary of medicines and devices (dm+d) terminology for each of the seven clinical conditions using the corresponding

Patient Group Directions which specify the exact drug, formulations and strengths that may be supplied as part of the consultation (6), see supplementary Table A1.

Data Analyses

Overview of the patient population using the Pharmacy First Clinical Pathway service recorded in OpenSAFELY-TPP

To describe the patient population using the Pharmacy First Clinical Pathway service, we conducted a patient-level analysis, reporting demographic (10-year age bands, sex, ethnicity in 16 categories) and regional (Indices of Multiple Deprivation quintiles derived from patients' postcodes at lower super output area, region) breakdowns. Data ascertainment covered the first year of service, from 31 January 2024 to 30 January 2025. To reduce the risk of re-identification, all counts smaller than or equal to 7 were redacted, then all counts were rounded to the nearest 5.

Monthly changes in Pharmacy First consultations in GP records

Patients with at least one recorded Pharmacy First consultation code were included in the study population. We reported monthly consultation counts to capture the total activity in GP records and annual patient count.

Comparison of Pharmacy First consultation counts in GP records and NHS BSA data

To contextualise the data used in this study, we compared overall consultation counts in OpenSAFELY-TPP with publicly available NHS BSA data, which captures 100% of Pharmacy First consultation activity that was reimbursed by NHS England (14). This comparison focused on aggregate consultation counts and the proportion of Pharmacy First consultations recorded in OpenSAFELY-TPP which represents approximately 40% of the population and NHS BSA data which represents 100% of reimbursement claims. We also compared counts of Pharmacy First consultations by clinical condition to assess the representativeness of our population.

Completeness of Pharmacy First consultation information in GP records

We examined the recording of clinical information recorded with Pharmacy First consultations by extracting clinical events and medications linked to each consultation using the consultation identifier. The code example in Box 1 illustrates how we query all clinical events and medications with the same consultation identifier as a Pharmacy First Consultation. Completeness was assessed to determine the extent to which key clinical information-specifically conditions and medications - is consistently recorded in structured data. Consultations were categorised in three mutually exclusive groups: (i) those with a recorded clinical condition from one of the seven pre-specified clinical conditions; (ii) those with a prescribed Pharmacy First medication; and (iii) those with both a recorded Pharmacy First-specific clinical condition and medication. Monthly proportions were calculated to assess changes in recording patterns over time.

Summary of clinical conditions recorded in Pharmacy First consultations

We identified Pharmacy First clinical conditions by extracting all SNOMED CT codes recorded during Pharmacy First consultations that matched the seven NHS England-defined clinical conditions. In order to support the wider evaluation of the implementation of Pharmacy First and to capture the full range of recorded consultations the inclusion and exclusion criteria associated with each pathway were not applied. Counts of clinical conditions were grouped by pathway and broken down by patient sex and Index of Multiple Deprivation (IMD) to get a better understanding of the population using the service for each condition. To compare clinical condition recording between data sources, we calculated the percentage of Pharmacy First consultations attributed to each of the seven NHS England-specified clinical conditions in OpenSAFELY-TPP and NHS BSA data.

Summary of medications recorded in Pharmacy First consultations

Medications issued during the Pharmacy First consultations were identified using dm+d codes recorded within the same consultation, and summarised as generic products (Virtual Medicinal Product [VMP] dm+d level). We restricted analysis to the ten most frequently recorded medications over the 12-month study period. Each medication was mapped to the relevant clinical condition(s) as specified in NHS England guidance. We identified the percentage of Pharmacy First consultations with and without a prescription as specified by NHS England.

Dashboard

We also developed a dashboard including further demographic, regional, and clinical breakdowns as part of this study (https://reports.opensafely.org/). This report will be updated regularly to reflect new information as available.

Software and Reproducibility

Data management was performed using Python v3.9.1 and R v4.0.5. Code for data management and analysis, as well as codelists, are available for review and reuse under the MIT open license at https://github.com/opensafely/pharmacy-first/.

Patient and public involvement

OpenSAFELY has involved patients and the public in various ways: we developed a public website that provides a detailed description of the platform in language suitable for a lay audience (https://opensafely.org); we have participated in two citizen juries exploring public trust in OpenSAFELY; we have co-developed an explainer video (https://www.opensafely.org/about/); we have patient representation who are experts by experience on our OpenSAFELY Oversight Board; we have partnered with Understanding Patient Data to produce lay explainers on the importance of large datasets for research; we have presented at various online public engagement events to key communities (e.g., Healthcare Excellence Through Technology; Faculty of Clinical Informatics annual conference; NHS Assembly; HDRUK symposium); and more. To ensure the patient voice is represented,

we are working closely to decide on language choices with appropriate medical research charities (e.g., Association of Medical Research Charities). We will share information and interpretation of our findings through press releases, social media channels, and plain language summaries. As part of this National Institute for Health and Care Research commissioned evaluation study we have established a specific PPIE panel. This quantitative study was commenced prior to the recruitment of the panel. We will present the results to our panel to inform all future work as well as disseminating our work publicly through various media.

Results

Overview of the patient population using the Pharmacy First Clinical Pathway service recorded in OpenSAFELY-TPP

Between 31 January 2024 and 30 January 2025, we identified 402,165 Pharmacy First consultations for 340,710 patients in a total of 26,142,380 registered patients in OpenSAFELY-TPP, see Table 1. The population recorded using the Pharmacy First service was predominantly female (67.3%) and showed higher service use among younger adults, with over half (59.3%) aged under 40. Most patients were of White British ethnicity (71.3%). A quarter of patients (25.4%) came from the most deprived IMD quintile, indicating higher recorded uptake in more deprived areas.

Table 1. Description of patient population with at least one Pharmacy First consultation code (*n* = 340,710) and total registered population in OpenSAFELY-TPP (*N* = 26,142,380).

	Pharmacy First		OpenSAFELY-TPP	
	Count	Percent	Count	Percent
Sex				
Female	229,190	67.3%	13,011,745	49.8%
Male	111,520	32.7%	13,130,635	50.2%
Age				
0 - 19	94,895	27.9%	5,775,555	22.1%
20 - 39	106,810	31.4%	7,059,395	27.0%
40 - 59	86,015	25.2%	6,780,960	25.9%
60 - 79	45,450	13.3%	5,176,600	19.8%
80+	7,545	2.2%	1,349,865	5.2%
Ethnicity				
Asian or Asian British				
Bangladeshi	2,735	0.8%	172,475	0.7%
Indian	12,355	3.6%	983,510	3.8%
Pakistani	14,720	4.3%	715,395	2.7%
Any other Asian background	7,110	2.1%	581,280	2.2%
Black or Black British				
African	7,290	2.1%	641,700	2.5%
Caribbean	1,635	0.5%	136,735	0.5%
Any other Black background	1,650	0.5%	143,570	0.5%
Mixed				
White and Asian	1,690	0.5%	121,910	0.5%
White and Black African	1,250	0.4%	103,770	0.4%
White and Black Caribbean	1,980	0.6%	120,470	0.5%
Any other mixed background	2,690	0.8%	216,510	0.8%
Other ethnic groups				
Chinese	1,160	0.3%	247,465	0.9%
Any other ethnic group	5,485	1.6%	500,815	1.9%
White				
British	242,975	71.3%	17,532,065	67.1%
Irish	1,475	0.4%	126,620	0.5%
Any other White background	26,810	7.9%	2,550,950	9.8%
(Missing)	7,695	2.3%	1,247,135	4.8%
IMD				
1 - Most deprived	86,690	25.4%	5,183,155	19.8%
2	67,620	19.9%	5,009,215	19.2%
3	63,645	18.7%	5,307,215	20.3%
4	56,835	16.7%	4,936,940	18.9%
5 - Least deprived	48,045	14.1%	4,534,735	17.3%
(Missing)	17,875	5.2%	1,171,120	4.5%
Region				
East	64,230	18.9%	5,929,050	22.7%
East Midlands	45,515	13.4%	4,528,605	17.3%
London	20,615	6.0%	1,757,575	6.7%
North East	23,280	6.8%	1,261,870	4.8%
North West	26,785	7.9%	2,402,230	9.2%
South East	20,085	5.9%	1,703,325	6.5%
South West	42,345	12.4%	3,633,710	13.9%
West Midlands	15,850	4.7%	1,042,385	4.0%
Yorkshire and The Humber	80,785	23.7%	3,791,585	14.5%
(Missing)	1,225	0.4%	92,045	0.4%

Notes. IMD = Index of Multiple Deprivation.

Monthly changes in Pharmacy First consultations in GP records

The monthly counts of patients with a recorded Pharmacy First consultation in OpenSAFELY-TPP broken down by individual Pharmacy First consultation codes are presented in Figure 1. All consultations were recorded either with the *Pharmacy First service* code or the *Community Pharmacist Consultation Service for minor illness* code*. Only the *Community Pharmacist Consultation Service for minor illness* code (see blue circles in Figure 1) is referenced in the GP Connect: Update Record technical documentation (17). Of the 402,165 Pharmacy First consultations, 209,900 (52.2%) were recorded using the SNOMED CT code for *Pharmacy First Service*, and 192,265 (47.8%) using the code for *Community Pharmacist Consultation Service for minor illness* (supplementary Figure A1). The SNOMED CT code for *Community Pharmacy First Service* was not used during the study period. During the first year of service, the number of patients recorded with the *Pharmacy First service* code remained relatively stable, fluctuating between 10,000 and 25,000 patients per month. In contrast, use of the recommended *Community Pharmacist Consultation Service for minor illness* code fluctuated between 5,000 and 11,000 from February 2024 to September 2024, followed by an increase to 37,565 in December 2024, before a decline in January 2025 to 34,615.

Figure 1. Monthly count of patients with a Pharmacy First consultation code in their GP records in OpenSAFELY-TPP, broken down by individual Pharmacy First consultation codes. CP = Community Pharmacy.

Comparison of Pharmacy First consultation counts in GP records and NHS BSA data

The total of Pharmacy First consultations we identified in OpenSAFELY-TPP was lower than the publicly available data from NHS BSA. The population in this study covers 40% of the total registered population in England, but our Pharmacy First consultation counts ranged from only 11.3% to 23.7% of the NHS BSA figures. Figure 2 shows the total monthly counts and

proportions of patients with a Pharmacy First consultation code in their GP records in OpenSAFELY-TPP.

The NHS BSA counts displayed a gradual increase in Pharmacy First consultation counts over time. However, two distinct periods of decline were observed. The first occurred between May and June 2024, where NHS BSA counts dipped, while OpenSAFELY-TPP data showed an increase. The second decline was observed between July and September 2024, where both counts exhibit a drop in consultation counts before increasing from September onwards. Despite these fluctuations, NHS BSA counts remained considerably higher than those recorded in OpenSAFELY-TPP throughout the study period.

Figure 2. Monthly counts and proportion of patients with a Pharmacy First consultation code in OpenSAFELY-TPP, which represents approximately 40% of the population and NHS BSA data which represents 100% of reimbursement claims.

Completeness of recorded Pharmacy First consultation information in OpenSAFELY-TPP

Not all Pharmacy First consultations had a recorded clinical condition or medication in OpenSAFELY-TPP. Figure 3 presents the monthly breakdown of Pharmacy First consultations recorded with either one of the seven specified Pharmacy First clinical conditions, a Pharmacy First-listed medication, or both. In February 2024, 4.5% of consultations had a recorded clinical condition, 0.7% included a prescribed medication, and 0.07% contained both. The proportion of consultations with only a clinical condition steadily increased over time, reaching 13.5% by January. In contrast, consultations with only medication remained low, fluctuating between 0.4% and 1.2% throughout the study period. The largest improvement was observed in consultations recorded with both a clinical condition and a medication, which initially remained low before rising to 6.4% in May 2024. This was followed by a dip in consultations which recorded both in August and September, before increasing drastically from October onwards - peaking at 22.0% in January 2025. By January 2025, 13.5% of consultations had a

clinical condition only, 0.8% a medication only, and 22.0% both, totalling 36.3% of Pharmacy First consultations with a recorded condition and/or medication.

Figure 3. Monthly breakdown of all Pharmacy First consultation codes with either a recorded Pharmacy First medication, clinical condition, or both in OpenSAFELY-TPP.

Summary of clinical conditions recorded in Pharmacy First consultations

Table 2 summarises the count of clinical conditions, as specified by NHS England, recorded during Pharmacy First consultations (i.e., 36.3% of all Pharmacy First consultations). Acute pharyngitis (28.9%) and uncomplicated UTI (28%) were the most frequently recorded conditions, together accounting for more than half of all Pharmacy First consultations. Acute otitis media (16.2%) and acute sinusitis (13.6%) were the next most common, while infected insect bites (7.5%), impetigo (2.9%) and herpes zoster (2.8%) were recorded less frequently. All conditions were more commonly recorded among female patients. The uncomplicated UTI pathway had 23,195 recorded cases in females but also included 55 male cases who would not be expected to meet the inclusion criteria.

Table 2. Clinical conditions recorded in Pharmacy First consultations grouped by sex in OpenSAFELY-TPP during the first 12 months following the services' launch date on 31 January 2024.

Clinical Condition (Inclusion Criteria*)	Sex					
	Female	%	Male	%	**Overall**	%
Acute otitis media (1 to 17 years)	7,365	54.8%	6,075	45.2%	13,440	16.2%
Acute pharyngitis (5 years and over)	15,030	62.9%	8,850	37.0%	23,895	28.9%
Acute sinusitis (12 years and over)	7,760	68.7%	3,470	30.7%	11,295	13.6%
Herpes zoster (18 years and over)	1,470	62.8%	860	36.8%	2,340	2.8%
Impetigo (1 year and over)	1,350	55.8%	1,070	44.2%	2,420	2.9%
Infected insect bites (1 year and over)	3,955	63.5%	2,270	36.5%	6,225	7.5%
Uncomplicated UTI (Women 16-64 years)	23,140	99.8%	55	0.2%	23,195	28.0%
Total	59,865	72.6%	22,545	27.4%	82,410	100%

The percentage of consultations attributed to each clinical condition in OpenSAFELY-TPP closely matched those reported in NHS BSA data, with differences ranging from 0.1% (herpes zoster), to 4.5% (acute pharyngitis), see supplementary Table A3.

Summary of medications recorded in Pharmacy First consultations

Table 3 presents the top 10 medications included in Pharmacy First medication codelists (supplementary Table A1) recorded in Pharmacy First consultations (i.e. 22.8% of all Pharmacy First consultations) at Virtual Medicinal Products (VMPs) level . Phenoxymethylpenicillin 250mg tablets (32.1%) and nitrofurantoin 100mg modified-release capsules (31%) were the most commonly recorded medications, making up over two-thirds of all Pharmacy First medications supplied. Phenazone 40mg/g / lidocaine 10mg/g ear drops (5.7%) and clarithromycin 500mg capsules (4.4%) were also frequently supplied. Other notable medications included fluticasone furoate and mometasone nasal sprays (3.4% and 3.3%), flucloxacillin (3.2%), various other formulations of phenoxymethylpenicillin, and amoxicillin oral suspensions, which were predominantly recorded in Acute Pharyngitis and Acute Otitis Media consultations. The top 10 medications accounted for 86.2% of all medications recorded in Pharmacy First consultations.

Table 3. Top ten medication counts and percentage recorded in Pharmacy First consultations during the first 12 months following the services' launch date on 31 January 2024.

Virtual Medicinal Products (VMPs)	Clinical Condition	Count	Percent
Phenoxymethylpenicillin 250mg tablets	5, 6	15,635	32.1%
Nitrofurantoin 100mg modified-release capsules	7	15,095	31.0%
Phenazone 40mg/g / Lidocaine 10mg/g ear drops	1	2,785	5.7%
Clarithromycin 500mg tablets	1, 3, 5, 6	2,140	4.4%
Fluticasone furoate 27.5micrograms/dose nasal spray	5	1,630	3.4%
Mometasone 50micrograms/dose nasal spray	5	1,615	3.3%
Flucloxacillin 500mg capsules	2, 3	1,575	3.2%
Phenoxymethylpenicillin 250mg/5ml oral solution	5, 6	1,555	3.2%
Amoxicillin 250mg/5ml oral suspension	1	1,315	2.7%
Amoxicillin 250mg/5ml oral suspension sugar free	1	940	1.9%

Notes. Medications are summarised at Virtual Medicinal Products (VMP) level. The *Clinical Condition* column indicates the conditions treated with each medication: 1 = acute otitis media; 2 = impetigo; 3 = infected insect bites; 4 = herpes zoster; 5 = acute sinusitis; 6 = acute pharyngitis; 7 = uncomplicated UTI. This table only includes the top 10 medications, making up 86.2% (*n* = 51,350) of the total Pharmacy First medications as specified by NHS England. We also found 2,700 medications recorded in PF consultations that were not specified by NHS England to be issued under the Pharmacy First service.

Discussion

Summary

Pharmacy First was introduced as part of the NHS recovery strategy following the COVID-19 pandemic to improve access to care for minor conditions and reduce pressure on general practice. Within a population of 26,142,380 registered patients, we observed a relatively stable 25,000 recorded Pharmacy First consultations between its launch on 31st Jan 2024 and 30th September 2024. This was followed by a steady increase to 56,495 by 31st January 2025. The most frequently recorded clinical conditions were acute pharyngitis (28.9%) and uncomplicated UTI (28.0%), with phenoxymethylpenicillin (32.1%%) and nitrofurantoin (31.0%) supplied most frequently. By January 2025, 36.3% of Pharmacy First consultations had a recorded clinical condition, medication, or both. The recorded Pharmacy First events we observed in OpenSAFELY-TPP represented 23.7% of consultations recorded by NHS BSA during the same period, and monthly trends were broadly consistent between datasets. Females, younger adults and those living in more deprived areas were recorded more in the Pharmacy First population compared with the general population.

Findings in Context

To date, we are aware of no published evaluations that have examined recorded Pharmacy First consultations using routine data. This study provides the first population-level assessment of recording of Pharmacy First activity in general practice records. Male patients were underrepresented, comprising only 32.7% of all Pharmacy First consultations overall, and 38.1% among those with a recorded clinical condition in consultations excluding urinary tract infection where we know there are substantial differences in incidence between males and females. This aligns with previous studies that found men in the general population were generally less likely to visit their GP for common conditions (22). Further investigation is needed to understand whether this reflects a lower actual usage of Pharmacy First or differences in consultation coding between sexes.

Only 36.3% of Pharmacy First consultations included a recorded clinical condition, medication or both. Clinical pathway consultations require predefined eligibility criteria, assessed at a gateway point before the consultation can proceed (6), typically including a suspected clinical condition. If a patient passes the gateway point, the consultation is recorded - even if the diagnosis is later confirmed to be negative. Therefore, 100% of Pharmacy First consultations are expected to include a clinical condition code as per the service specification.

Our findings suggest that the demographic using the Pharmacy First service is different from the overall registered population in OpenSAFELY-TPP. The 0-19 and 20-39 age groups accounted for 27.9% and 31.4% of Pharmacy First consultations, respectively - higher than their representation in the general OpenSAFELY-TPP population (22.1% and 27.0%). We also observed that the proportion of patients recorded as White British among those who had a Pharmacy First consultation in the study period (71.3%) was slightly higher than in the general

OpenSAFELY-TPP population (67.1%). Consultation counts recording increased with greater deprivation, with uptake lowest in the least deprived (14.1%) areas and highest in the most deprived areas (25.4%). If this pattern persists and is similar in the missing data, Pharmacy First may contribute more to expanding access for previously under-served populations than to reducing overall GP workload. This would align with longstanding patterns of pharmacy provision: community pharmacies are more prevalent in deprived areas than general practices and may already function as a first point of contact where GP access is limited (18). However, we are not asserting cause for the observed effects, recording will be affected by the overall incidence of the common conditions in various groups, access to NHS services amongst those groups, GP recording patterns and much more.

The sharp increase in recorded consultations from September 2024 to January 2025 may be attributable to seasonal variations in demand, increased service awareness, or improvements in data recording practices. Another possible explanation relates to technical issues which were addressed following August 2024 (19) which may have led to a backlog of Pharmacy First consultations being transferred into GP records. Improved technical implementation might have also contributed to the proportion of consultations with a recorded clinical condition or medication increasing substantially after September 2024.

The substantially higher consultation counts observed in NHS BSA data may be explained by several factors. Firstly, NHS BSA data captures 100% of reimbursed Pharmacy First consultations, whereas OpenSAFELY-TPP covers only approximately 40% of the English population. Secondly, in addition to the aforementioned technical issues, an issue with data transfer to GPs arose through collective action by some GPs temporarily opting out of *GP Connect: Update Record* during the rollout phase (20) which may have led to under-recording in GP systems. Finally, regional underrepresentation in OpenSAFELY-TPP - most notably London, as discussed later - may also contribute to the observed difference.

Strengths and Limitations

The primary strength of this study is the use of OpenSAFELY-TPP, a secure and scalable dataset covering 26 million patients across 2,540 general practices in England. Despite lower coverage in comparison with NHS BSA, OpenSAFELY-TPP enables consultation-level analysis of structured clinical data, including clinical conditions and medications - which are not available in NHS BSA's aggregate reports. This makes it possible to evaluate how Pharmacy First is recorded in practice and how it varies across patient groups.

Furthermore, the dataset is largely representative of the national population with regards to IMD, age, sex, and ethnicity, making the findings generalisable to England (21). Additionally, this study is the first to evaluate the recording of Pharmacy First consultations in GP records at scale, providing insight into service uptake, data quality, and integration into primary care systems.

One limitation is the inclusive definition of a Pharmacy First consultation used in this study, which incorporates multiple SNOMED CT codes, and may capture a wider range of consultation types than the stricter NHS BSA definition. Additionally, London is

underrepresented in OpenSAFELY-TPP, which may limit the generalisability of findings to more urban populations. Comparing data on Pharmacy First from GPs with community pharmacy reimbursement data, indicates that not all Pharmacy First consultations are recorded consistently in line with services specifications, which may limit the conclusions that can be drawn from future quantitative studies. Furthermore, this analysis included all GP practices using the TPP software provider, so did not cover the full English population. OpenSAFELY has been used to deliver analysis across the full English GP population of circa 60 million records (22,23). However, access to EMIS data (used by the remaining GPs) is currently paused, whilst NHS England concludes formal commercial and data processing agreements with EMIS (24).

Policy Implications

Improving routine data quality and infrastructure

Data completeness improved substantially over the study period, likely due to rollout technical solutions and increased familiarity with the system. Although 100% completeness is anticipated in the long term, this was unlikely during the first year, given the rapid launch of the service and scale of changes required. This reflects the real-world challenges of implementing national infrastructure that will benefit similar schemes in the future. Future services should be supported by timely publication of technical documentation, including SNOMED CT codes to support transparency and independent evaluations. The temporary suspension of *GP Connect: Update Record* functionality in some practices during industrial action highlights the need for systems that are resilient to disruption, and developed with broad consensus in advance. More broadly, our findings reinforce the importance of effective digital integration between community pharmacy and general practice to ensure complete and accurate clinical documentation. Strengthening data linkage and addressing technical barriers will enhance service monitoring and evaluation, and support the seamless integration of Pharmacy First within routine general practice workflows.

Pharmacy First and access to primary care

Pharmacy First was launched to improve access to timely care for minor conditions, in the context of the COVID-19 pandemic backlogs and the NHS recovery plans. Early findings suggest that the service is being used more by younger patients and those living in more deprived areas, potentially reversing the inverse care law observed in general practice (25). This may partly be explained by the finding that community pharmacies are more clustered in the most deprived areas (26). While this study was not designed to evaluate this directly, these patterns suggest that these populations might be able to more easily access services in pharmacies although we can draw limited conclusions until structured recording is more in line with actual use of the service

To support ongoing evaluation of equitable access, we developed a public dashboard (https://reports.opensafely.org/) presenting stratified, near real-time data on Pharmacy First consultations. This tool enables policymakers and clinicians to monitor service uptake to improve rapid decision-making, enabling targeted improvements in service delivery.

Future Research

This initial analysis forms the foundation for a broader programme of research designed to explore the wider impact of the new Pharmacy First service on primary care service use and prescribing (11). The evaluation will use mixed methods with five elements, namely, evidence synthesis, semi-structured interviews, focus groups, quantitative analysis of impacts before and after implementation (e.g. using interrupted time series analysis) using routine data, and an economic evaluation. We will generate evidence to show: whether PF contributes to improving primary healthcare access, assessing the quality of antimicrobial use, identifying the scope for refinements to PF, and, overall, informing better implementation of PF. The findings will also provide robust evidence to enable policymakers to determine the role of community pharmacy in England in the future.

As part of this study we have generated new research questions around particular findings. For example, a more detailed investigation is needed into the reasons why some Pharmacy First consultations lack a recorded clinical condition or medication, including the role of technical limitations, manual data entry, or incomplete uptake of *GP Connect: Update Record*. Additional validation work should examine how well the patients seen match the pathway inclusion and exclusion criteria. For example, our results identified small numbers of seemingly ineligible male patients recorded under the uncomplicated UTI pathway, as well as instances of medications being coded that are not specified by NHSE to be issued under the Pharmacy First service; it is not currently clear whether this reflects a data quality issue, misapplication of eligibility criteria, or another factor. To fully interpret our quantitative studies, qualitative research is needed and planned as part of the wider evaluation, to capture the experiences and perspectives of pharmacists, GPs, and patients. In particular, qualitative work should focus on groups underrepresented in the current population using the Pharmacy First service.

More broadly, the technical tools and infrastructure is available to any researcher conducting work in OpenSAFELY. This will not only support future studies on focused Pharmacy First but also other studies where Pharmacy First may be relevant. Finally, OpenSAFELY can now facilitate the ability to, in near real time, monitor the continued rollout of Pharmacy First

Conclusion

This study provides the first large-scale analysis of Pharmacy First consultation recording in general practice records. Recorded uptake has increased over time, with higher consultation counts observed among younger age groups and patients from more deprived areas. Although NHS England indicated that detailed information would be reliably captured and transferred into GP records, data completeness in structured GP records remains a key limitation. Some Pharmacy First activity currently appears not to be recorded in GP records and the majority of consultations have no recorded clinical condition or medication. Addressing both gaps through improved technical integration and standardised recording will be essential to support robust evaluations of the service and its impact. We invite others to expand on our initial work using OpenSAFELY.

Administrative

Funding

The OpenSAFELY platform is principally funded by grants from:

NHS England [2023-2025]; The Wellcome Trust (222097/Z/20/Z) [2020-2024]; MRC (MR/V015737/1) [2020-2021].

Additional contributions to OpenSAFELY have been funded by grants from:

MRC via the National Core Study programme, Longitudinal Health and Wellbeing strand (MC_PC_20030, MC_PC_20059) [2020-2022] and the Data and Connectivity strand (MC_PC_20058) [2021-2022]; NIHR and MRC via the CONVALESCENCE programme (COV-LT-0009, MC_PC_20051) [2021-2024]; NHS England via the Primary Care Medicines Analytics Unit [2021-2024]. This project was funded by a grant from the National Institute for Health and Care Research [NIHR160217].

Diane Ashiru-Oredope is funded by NIHR Senior Clinical and Practitioner Award (NIHR304553).

The views expressed are those of the authors and not necessarily those of the NIHR, NHS England, UK Health Security Agency (UKHSA), the Department of Health and Social Care, or other funders. Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Conflicts of Interest Statement

All authors declare the following: BG has received research funding from the Bennett Foundation, the Laura and John Arnold Foundation, the NHS National Institute for Health Research (NIHR), the NIHR School of Primary Care Research, NHS England, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK, the Health Foundation, the World Health Organisation, UKRI MRC, Asthma UK, the British Lung Foundation, and the Longitudinal Health and Wellbeing strand of the National Core Studies programme; he has previously been a Non-Executive Director at NHS Digital; he also receives personal income from speaking and writing for lay audiences on the misuse of science. BMK is also employed by NHS England working on medicines policy and clinical lead for primary care medicines data. AJA is National Clinical Director for Prescribing for NHS England.

Information Governance and Ethical Approval

NHS England is the data controller of the NHS England OpenSAFELY COVID-19 Service; TPP is the data processor; all study authors using OpenSAFELY have the approval of NHS England.[3] This implementation of OpenSAFELY is hosted within the TPP environment which is accredited to the ISO 27001 information security standard and is NHS IG Toolkit compliant;[4]

Patient data has been pseudonymised for analysis and linkage using industry standard cryptographic hashing techniques; all pseudonymised datasets transmitted for linkage onto OpenSAFELY are encrypted; access to the NHS England OpenSAFELY COVID-19 service is via a virtual private network (VPN) connection; the researchers hold contracts with NHS England and only access the platform to initiate database queries and statistical models; all database activity is logged; only aggregate statistical outputs leave the platform environment following best practice for anonymisation of results such as statistical disclosure control for low cell counts.[5]

The service adheres to the obligations of the UK General Data Protection Regulation (UK GDPR) and the Data Protection Act 2018. The service previously operated under notices initially issued in February 2020 by the the Secretary of State under Regulation 3(4) of the Health Service (Control of Patient Information) Regulations 2002 (COPI Regulations), which required organisations to process confidential patient information for COVID-19 purposes; this set aside the requirement for patient consent.[6] As of 1 July 2023, the Secretary of State has requested that NHS England continue to operate the Service under the COVID-19 Directions 2020.[7] In some cases of data sharing, the common law duty of confidence is met using, for example, patient consent or support from the Health Research Authority Confidentiality Advisory Group.[8]

Taken together, these provide the legal bases to link patient datasets using the service. GP practices, which provide access to the primary care data, are required to share relevant health information to support the public health response to the pandemic, and have been informed of how the service operates.

This study was supported by Anne Joshua (Deputy Director of Pharmacy Commissioning & Head of Pharmacy Integration, NHS England) as senior sponsor, and approved by the Health Research Authority (REC reference 20/LO/0651). (NHS England service evaluations/audits are currently not required to have Ethics approval.)

1. NHS Digital. The NHS England OpenSAFELY COVID-19 service - privacy notice [Internet]. 2023 [cited 2023 Jul 4]. Available from: https://digital.nhs.uk/coronavirus/coronavirus-covid-19-response-information-governance-hub/the-nhs-england-opensafely-covid-19-service-privacy-notice
2. NHS Digital. Secretary of State for Health and Social Care - UK Government. COVID-19 Public Health Directions 2020: notification to NHS Digital [Internet]. 2023 [cited 2023 Jul 4]. Available from:

https://web.archive.org/web/20250414105355/https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/directions-and-data-provision-notices/data-provision-notices-dpns/opensafely-covid-19-service-data-provision-notice

3. NHS Digital. ISB1523: Anonymisation Standard for Publishing Health and Social Care Data [Internet]. 2023 [cited 2023 Jul 4]. Available from: https://web.archive.org/web/20250430135246/standards.nhs.uk/published-standards/anonymisation-standard-for-publishing-health-and-social-care-data

4. NHS Digital. Data Security and Protection Toolkit [Internet]. 2023 [cited 2023 Jul 4]. Available from: https://web.archive.org/web/20250405100349/https://digital.nhs.uk/services/data-security-and-protection-toolkit/data-security-and-protection-toolkit

5. NHS Digital. Coronavirus (COVID-19): notice under regulation 3(4) of the Health Service (Control of Patient Information) Regulations 2002 – general [Internet]. 2022 [cited 2023 Jul 5]. Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-notification-of-data-controllers-to-share-information/coronavirus-covid-19-notice-under-regulation-34-of-the-health-service-control-of-patient-information-regulations-2002-general--2

6. Health Research Authority. Confidentiality Advisory Group [Internet]. 2023 [cited 2023 Jul 4]. Available from: https://web.archive.org/web/20250408154826/https://www.hra.nhs.uk/about-us/committees-and-services/confidentiality-advisory-group/

Acknowledgements

We are very grateful for all the support received from the TPP Technical Operations team throughout this work, and for generous assistance from the information governance and database teams at NHS England and the NHS England Transformation Directorate.

References

1. NHS England. Appointments in General Practice. 2025 [cited 2025 Apr 15]. Appointments in General Practice. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/appointments-in-general-practice

2. British Medical Association. Pressures in general practice data analysis. 2025 [cited 2025 Apr 15]. Pressures in general practice data analysis. Available from: https://www.bma.org.uk/advice-and-support/nhs-delivery-and-workforce/pressures/pressures-in-general-practice-data-analysis

3. NHS England. Community Pharmacy Contractual Framework 2019-2024 [Internet]. 2024 [cited 2025 Apr 15]. Available from: https://www.england.nhs.uk/primary-care/pharmacy/community-pharmacy-contractual-framework/

4. NHS England. Delivery plan for recovering access to primary care [Internet]. 2023. Available from: https://www.england.nhs.uk/long-read/delivery-plan-for-recovering-access-to-primary-care-2/

5. NHS England. Pharmacy services: Pharmacy First [Internet]. 2024 [cited 2025 Feb 26]. Available from: https://www.england.nhs.uk/primary-care/pharmacy/pharmacy-services/pharmacy-first/

6. NHS England. Community Pharmacy advanced service specification: NHS Pharmacy First Service [Internet]. 2023 [cited 2025 Feb 26]. Available from: https://www.england.nhs.uk/publication/community-pharmacy-advanced-service-specification-nhs-pharmacy-first-service/

7. NHS England. GP Connect Update Record [Internet]. 2023 [cited 2025 Feb 26]. Available from: https://digital.nhs.uk/developer/api-catalogue/gp-connect-update-record

8. NHS England. GP Connect: Update Record [Internet]. 2024 [cited 2025 Feb 26]. Available from: https://digital.nhs.uk/services/gp-connect/gp-connect-in-your-organisation/gp-connect-update-record

9. NHS England. GP Connect Update Record: FAQs [Internet]. 2025 [cited 2025 Mar 19]. Available from: https://www.england.nhs.uk/long-read/gp-connect-update-record-faqs/

10. Community Pharmacy England. Reminder: GP Connect: Update Record rollout. 2024 [cited 2025 Feb 26]; Available from: https://web.archive.org/web/20240425094253/https://cpe.org.uk/our-news/gp-connect-update-record-rollout-and-flow-of-information/

11. Glover RE, Lalani M, Sonnex K, Allen T, Anderson C, Ashiru-Oredope D, et al. A mixed methods protocol for an impact and implementation evaluation of the Pharmacy First

Services for management of common conditions in England. Int J Pharm Pract [Internet]. 2025 Mar 5 [cited 2025 Apr 14]; Available from: https://doi.org/10.1093/ijpp/riaf004

12.   Cunningham C, Fisher L, Wood C, Speed V, Brown AD, Curtis H, et al. Incidence and treatment of group A streptococcal infections during covid-19 pandemic and 2022 outbreak: retrospective cohort study in England using OpenSAFELY-TPP. BMJ Med [Internet]. 2024 May 24 [cited 2025 Mar 24];3(1). Available from: https://bmjmedicine.bmj.com/content/3/1/e000791

13.   Wood C, Speed V, Fisher L, Curtis HJ, Schaffer AL, Walker AJ, et al. The impact of COVID-19 on medication reviews in English primary care. An OpenSAFELY-TPP analysis of 20 million adult electronic health records. Br J Clin Pharmacol. 2024 Jul;90(7):1600–14.

14.   NHS Business Service Authority. Dispensing contractors' data [Internet]. 2025 [cited 2025 Feb 26]. Available from: https://www.nhsbsa.nhs.uk/prescription-data/dispensing-data/dispensing-contractors-data

15.   NHS England. Personal communication. 2024.

16.   NHS England. Pharmacy First Clinical Pathways [Internet]. 2023 [cited 2025 Feb 26]. Report No.: v. 1.6. Available from: https://www.england.nhs.uk/wp-content/uploads/2023/11/PRN00936_ii_Pharmacy-First-Clinical-Pathways-v.1.6.pdf

17.   NHS England. GP Connect - Update Record (ITK3) [Internet]. [cited 2025 Feb 26]. Available from: https://simplifier.net/guide/gp-connect--update-record--itk3/Home/FHIR-Assets/All-assets/Profiles/Profile--CareConnect-Composition-1?version=1.2.0-public-beta

18.   Fisher R, Allen L, Malhotra A, Alderwick H. Tackling the inverse care law: Analysis of policies to improve general practice in deprived areas since 1990 [Internet]. The Health Foundation; 2022 Jan [cited 2025 Apr 17]. Available from: https://www.health.org.uk/publications/reports/tackling-the-inverse-care-law

19.   Community Pharmacy England. ACTION: For pharmacy owners who use or have previously used PharmOutcomes [Internet]. 2024 [cited 2025 Apr 15]. Available from: https://web.archive.org/web/20250125232731/https://cpe.org.uk/our-news/action-for-pharmacy-owners-who-use-or-have-previously-used-pharmoutcomes/

20.   NHS England. Collective action by GPs: supporting guidance [Internet]. 2025 [cited 2025 Jun 5]. Available from: https://www.england.nhs.uk/long-read/collective-action-by-gps-supporting-guidance/

21.   Andrews C, Schultze A, Curtis H, Hulme W, Tazare J, Evans S, et al. OpenSAFELY: Representativeness of electronic health record platform OpenSAFELY-TPP data compared to the population of England. Wellcome Open Res. 2022;7:191.

22.   Fisher L, Speed V, Curtis HJ, Rentsch CT, Wong AYS, Schultze A, et al. Potentially inappropriate prescribing of DOACs to people with mechanical heart valves: A federated analysis of 57.9 million patients' primary care records in situ using OpenSAFELY. Thromb Res. 2022 Mar 1;211:150–3.

23.   Fisher L, Curtis HJ, Croker R, Wiedemann M, Speed V, Wood C, et al. Eleven key

measures for monitoring general practice clinical activity during COVID-19: A retrospective cohort study using 48 million adults' primary care records in England through OpenSAFELY. Malagón T, Franco EL, Shah A, editors. eLife. 2023 Jul 27;12:e84673.

24. Bennett Institute for Applied Data Science. OpenSAFELY Update – July 2024 [Internet]. 2024. Available from: https://www.opensafely.org/changelog/#2024-07-24

25. Gopfert A, Deeny SR, Fisher R, Stafford M. Primary care consultation length by deprivation and multimorbidity in England: an observational study using electronic patient records. Br J Gen Pract. 2021 Mar 1;71(704):e185–92.

26. Todd A, Thomson K, Kasim A, Bambra C. Cutting care clusters: the creation of an inverse pharmacy care law? An area-level analysis exploring the clustering of community pharmacies in England. BMJ Open. 2018 Oct 1;8(7):e022109.

Online Supplemental Materials

Table A1. Codelists used to identify Pharmacy First consultations, clinical events, and medications.

Category	Codelist
PF Consultations	opensafely/pharmacy-first-consultation
PF Clinical Conditions	user/chriswood/pharmacy-first-clinical-pathway-conditions
PF Medications	
Acute Otitis Media	opensafely/pharmacy-first-acute-otitis-media-treatment-full-dmd-codelist
Impetigo	opensafely/pharmacy-first-impetigo-treatment-full-dmd-codelist
Infected Insect Bites	opensafely/pharmacy-first-infected-insect-bites-treatment-full-dmd-codelist
Herpes Zoster	codelist/opensafely/pharmacy-first-shingles-treatment-full-dmd-codelist
Acute Sinusitis	codelist/opensafely/pharmacy-first-sinusitis-treatment-full-dmd-codelist
Acute Pharyngitis	opensafely/pharmacy-first-sore-throat-treatment-full-dmd-codelist
UTI	opensafely/pharmacy-first-urinary-tract-infection-treatment-full-dmd-codelist

Notes. PF = Pharmacy First; UTI = Urinary Tract Infections.

Table A2. Count of clinical conditions linked to Pharmacy First consultations in OpenSAFELY-TPP grouped by IMD during the first 12 months following the services' launch.

Clinical Condition (Inclusion Criteria*)	Index of Multiple Deprivation (IMD)				
	1 (most deprived)	2	3	4	5 (least deprived)
Acute otitis media (1 to 17 years)	3,305	2,305	2,315	2,360	2,055
Acute pharyngitis (5 years and over)	6,685	5,070	4,145	3,710	3,040
Acute sinusitis (12 years and over)	2,335	1,970	2,215	2,240	1,940
Herpes zoster (18 years and over)	410	380	460	505	450
Impetigo (1 year and over)	630	445	415	435	360
Infected insect bites (1 year and over)	1,335	1,150	1,255	1,215	1,000
Uncomplicated UTI (Women 16-64 years)	5,295	4,300	4,390	4,350	3,680

Notes. UTI = Urinary Tract Infections.* To capture the entire service activity, inclusion criteria as specified by NHS England were not applied but are presented for reference.

Table A3. Comparison of clinical condition recorded in Pharmacy First consultations in OpenSAFELY-TPP and NHS BSA during the first 12 months following the services' launch.

Clinical Condition (Inclusion Criteria*)	OpenSAFELY-TPP		NHS BSA	
	Count**	Percent	Count**	Percent
Acute otitis media (1 to 17 years)	13,440	16.2%	260,590	11.8%
Acute pharyngitis (5 years and over)	23,895	28.9%	736,647	33.4%
Acute sinusitis (12 years and over)	11,295	13.6%	248,702	11.3%
Herpes zoster (18 years and over)	2,340	2.8%	58,361	2.7%
Impetigo (1 year and over)	2,420	2.9%	736,647	4.3%
Infected insect bites (1 year and over)	6,225	7.5%	198,069	9.0%
Uncomplicated UTI (Women 16-64 years)	23,195	28.0%	607,646	27.5%

Notes. UTI = Urinary tract infections. * To capture the entire service activity, inclusion criteria as specified by NHS England were not applied but are presented for reference.

** OpenSAFELY-TPP counts in this table represent one condition per patient; NHS BSA counts capture all observed conditions, including multiple per patient. For the purpose of this comparison, we assume that this does not significantly impact the proportional representation of each condition.